Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Oncology and Immunology<br />
about the book…<br />
Recent advances in immunology and biology have opened new horizons in cancer<br />
therapy, included in the expanding array of cancer treatment options, which<br />
are immunotherapies, or cancer vaccines, for both solid and blood borne cancers.<br />
Cancer Vaccines: Challenges and Opportunities in Translation is the first text in<br />
the field to bring immunotherapy treatments from the laboratory trial to the bedside<br />
for the practicing oncologist.<br />
Cancer Vaccines: Challenges and Opportunities in Translation:<br />
• Critically analyzes the most promising classes of investigational immunotherapies,<br />
integrating their scientific rationale and clinical potential<br />
• Discusses “theranostics” as pertaining to immunotherapy, i.e., using molecular<br />
diagnostics to identify patients that would most likely benefit from a therapy<br />
• Presents the new paradigm of biomarker guided R&D and clinical development<br />
in immunotherapy of cancer<br />
• Reviews bottlenecks in translational process of immunotherapies and offers<br />
strategies to resolve them<br />
about the editors...<br />
ADRIAN BOT is Senior Director of Scientific Management and Acting Head of<br />
Translational Medicine at MannKind Corporation, in Valencia, California. He obtained<br />
his M.D. at the University of Medicine and <strong>Ph</strong>armacy in Timisoara, Romania and his<br />
<strong>Ph</strong>.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York.<br />
He previously held appointments at the Scripps Research Institute and Alliance<br />
<strong>Ph</strong>armaceutical Corporation in San Diego. Dr. Bot authored more than one hundred<br />
publications and patents in oncology, vaccines, drug delivery technologies and<br />
immunotherapy. He is the Editor-in-Chief of the International Reviews of Immunology<br />
and has been on advisory boards of several organizations.<br />
MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation,<br />
Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine<br />
and <strong>Ph</strong>armacy, Bucharest, Romania. He is a medical oncologist with over 10 years of<br />
academic and industry experience in oncology clinical trials, including biologic<br />
agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology<br />
peer-reviewed literature, and has various patents in the field of biotechnology.<br />
Printed in the United States of America<br />
�����